IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of GT Biopharma, Inc. (Nasdaq: GTBP). The Wealth Advisory is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, GT Biopharma, Inc. (Nasdaq: GTBP) is the sole source of funds for a budget of approximately $3,335,724 provided to the advertising agency to cover the costs associated with creating, printing and distribution of this advertisement. The Wealth Advisorymay receive subscription revenue in the future from new subscribers as a result of this advertisement for its newsletter. The advertising agency will retain any excess sums after all expenses are paid. While this advertisement is being disseminated and for a period of not less than 90 days thereafter, The Wealth Advisory, the advertising agency, and their respective officers, principals, or affiliates will not sell securities of GT Biopharma, Inc. (Nasdaq: GTBP). If successful, this advertisement will increase investor and market awareness of GT Biopharma, Inc. (Nasdaq: GTBP) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement, the advertising agency and The Wealth Advisory do not purport to provide a complete analysis of GT Biopharma, Inc. (Nasdaq: GTBP) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about GT Biopharma, Inc. (Nasdaq: GTBP). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in GT Biopharma, Inc. (Nasdaq: GTBP) SEC filings. Investing in microcap securities such as GT Biopharma, Inc. (Nasdaq: GTBP) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agency and The Wealth Advisory cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of GT Biopharma, Inc. (Nasdaq: GTBP) and/or its industry. The advertising agency and The Wealth Advisory note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect GT Biopharma, Inc. (Nasdaq: GTBP) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for GT Biopharma, Inc. (Nasdaq: GTBP) products and/or services, the company's ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. The Wealth Advisory is the publisher's trademark. All trademarks used in this advertisement other than The Wealth Advisory are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agency and The Wealth Advisory are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.
DISCLOSURES - THIS IS A PAID ADVERTISEMENT.
This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclosure, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.
In connection with this advertising e-mail campaign, The Darwin Agency, Inc, DBA Darwin Investor Network, and its owners, managers, employees, and assigns Creative Direct Marketing Group has been paid by the profiled company or a third party to disseminate this communication. In this case, the Company has been paid by GT Biopharma, Inc $2,000USD. This compensation is a major conflict with our ability to be unbiased.
NOT AN INVESTMENT ADVISER. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.
ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on the highlighted companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.
For official filings and investor disclosures, visit:
GT Biopharma, Inc SEDAR+ Filings
GT Biopharma, Inc Investor Relations Page
By reading this communication, you agree to the terms of this disclaimer, including releasing the Company, its affiliates, owners, and assigns from any and all liability, damages, or injury resulting from the information contained herein. You acknowledge that you are solely responsible for any financial or investment decisions based on this communication.
0 Response to "This little-known biotech’s cancer breakthrough could be a gold mine"
Post a Comment